Faron Pharmaceuticals Oy (LON:FARN - Get Free Report) shares were down 14% during mid-day trading on Wednesday . The company traded as low as GBX 197.66 ($2.63) and last traded at GBX 200 ($2.66). Approximately 412,469 shares traded hands during mid-day trading, an increase of 1,280% from the average daily volume of 29,893 shares. The stock had previously closed at GBX 232.50 ($3.09).
Faron Pharmaceuticals Oy Trading Up 8.4 %
The company has a debt-to-equity ratio of 922.55, a current ratio of 1.45 and a quick ratio of 1.09. The company has a market capitalization of £285.15 million, a price-to-earnings ratio of -5.68 and a beta of 0.36. The business has a fifty day moving average price of GBX 191.56 and a 200 day moving average price of GBX 185.33.
About Faron Pharmaceuticals Oy
(
Get Free Report)
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
Further Reading
Before you consider Faron Pharmaceuticals Oy, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Faron Pharmaceuticals Oy wasn't on the list.
While Faron Pharmaceuticals Oy currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
